Asset Management One Co. Ltd. Has $14.11 Million Stock Holdings in ResMed Inc. (NYSE:RMD)

Asset Management One Co. Ltd. raised its position in ResMed Inc. (NYSE:RMD - Free Report) by 2.8% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 60,489 shares of the medical equipment provider's stock after acquiring an additional 1,629 shares during the period. Asset Management One Co. Ltd.'s holdings in ResMed were worth $14,105,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently made changes to their positions in the stock. Ascent Group LLC increased its position in shares of ResMed by 1.7% during the 3rd quarter. Ascent Group LLC now owns 2,924 shares of the medical equipment provider's stock worth $714,000 after purchasing an additional 48 shares during the last quarter. SkyView Investment Advisors LLC increased its position in shares of ResMed by 2.0% during the 3rd quarter. SkyView Investment Advisors LLC now owns 2,610 shares of the medical equipment provider's stock worth $637,000 after purchasing an additional 51 shares during the last quarter. Wedmont Private Capital increased its position in shares of ResMed by 2.6% during the 4th quarter. Wedmont Private Capital now owns 2,032 shares of the medical equipment provider's stock worth $475,000 after purchasing an additional 52 shares during the last quarter. Concurrent Investment Advisors LLC increased its position in shares of ResMed by 3.1% during the 3rd quarter. Concurrent Investment Advisors LLC now owns 1,919 shares of the medical equipment provider's stock worth $469,000 after purchasing an additional 57 shares during the last quarter. Finally, Brooklyn Investment Group increased its position in shares of ResMed by 8.1% during the 4th quarter. Brooklyn Investment Group now owns 911 shares of the medical equipment provider's stock worth $208,000 after purchasing an additional 68 shares during the last quarter. Institutional investors and hedge funds own 54.98% of the company's stock.

ResMed Stock Performance

NYSE RMD traded down $1.63 on Thursday, reaching $232.89. The stock had a trading volume of 662,267 shares, compared to its average volume of 968,523. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.33 and a quick ratio of 2.29. The firm has a fifty day moving average of $237.76 and a two-hundred day moving average of $239.01. ResMed Inc. has a 1-year low of $170.56 and a 1-year high of $263.05. The company has a market cap of $34.20 billion, a P/E ratio of 27.50, a price-to-earnings-growth ratio of 1.52 and a beta of 0.70.

ResMed (NYSE:RMD - Get Free Report) last issued its quarterly earnings data on Thursday, January 30th. The medical equipment provider reported $2.43 EPS for the quarter, beating analysts' consensus estimates of $2.29 by $0.14. ResMed had a return on equity of 26.17% and a net margin of 25.34%. On average, equities research analysts anticipate that ResMed Inc. will post 9.44 EPS for the current year.

ResMed Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 13th will be given a dividend of $0.53 per share. The ex-dividend date is Thursday, February 13th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.91%. ResMed's payout ratio is 25.03%.

Analysts Set New Price Targets

Several research firms have weighed in on RMD. Piper Sandler boosted their price target on ResMed from $252.00 to $260.00 and gave the stock a "neutral" rating in a research report on Friday, January 31st. Robert W. Baird boosted their target price on ResMed from $280.00 to $283.00 and gave the stock an "outperform" rating in a report on Friday, October 25th. UBS Group raised ResMed from a "hold" rating to a "strong-buy" rating in a report on Friday, January 31st. Needham & Company LLC reissued a "hold" rating on shares of ResMed in a report on Friday, January 31st. Finally, KeyCorp boosted their target price on ResMed from $266.00 to $280.00 and gave the stock an "overweight" rating in a report on Friday, January 31st. One research analyst has rated the stock with a sell rating, six have given a hold rating, seven have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $244.73.

Insider Activity

In related news, insider Justin Leong sold 6,160 shares of the company's stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $243.09, for a total transaction of $1,497,434.40. Following the completion of the sale, the insider now directly owns 21,718 shares in the company, valued at $5,279,428.62. This represents a 22.10 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Michael J. Farrell sold 8,009 shares of the stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $236.77, for a total value of $1,896,290.93. Following the completion of the transaction, the chief executive officer now owns 455,472 shares of the company's stock, valued at $107,842,105.44. This represents a 1.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 18,307 shares of company stock worth $4,403,180. 0.71% of the stock is currently owned by company insiders.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.